From Medscape Neurology

Coverage from the

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017

February 23 - 25, 2017; Orlando, Florida

February 23 - 25, 2017 Orlando, Florida
  • ACTRIMS Ocrelizumab Not Linked to Serious Infection Risk in MS Further OPERA and ORATORIO results show similar or even lower rates of severe infection in patients receiving the study drug vs interferon or placebo, researchers say, as well as better patient-reported outcomes.
  • ACTRIMS Retinal Degeneration Ongoing in Pediatric MS Children with multiple sclerosis showed more progressive ganglion cell layer thinning than healthy kids or those with monophasic demyelination -- and there was more retinal atrophy in girls than in boys.
  • ACTRIMS Stem Cell Transplantation May Decrease MS-Related Fatigue Although treating fatigue shouldn't be the main reason for performing this procedure, it is an added bonus, say investigators. But they caution that it requires 'utmost discretion.'

Conference News

Popular News from ACTRIMS 2016

  • Ocrelizumab Benefit in Primary Progressive MS Consistent in Subgroups Ocrelizumab Benefit Consistent in Progressive MS Subgroup analysis of the phase 3 ORATORIO trial found patients with T1 Gd-positive and Gd-negative lesions experienced benefits in line with those of the whole study population after treatment with ocrelizumab.
  • Disease Suppression Persists With Ozanimod at 72 Weeks in MS Disease Suppression Persists With Ozanimod at 72 Weeks in MS The 48-week extension of the RADIANCE trial showed persistent benefit for ozanimod, reduced gadolinium-enhancing lesions, and a low relapse rate.
  • Biomarkers May Predict Progression in MS Biomarkers May Predict Progression in MS Researchers have identified a proinflammatory profile in CSF that may correlate with cortical pathology and could prove useful to stratify patients with early progressive multiple sclerosis.

Medscape Neurology©  WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

ACTRIMS on Twitter